Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $46.00 price objective on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Tuesday, January 28th.

Anavex Life Sciences Trading Up 4.9 %

Shares of NASDAQ:AVXL opened at $8.70 on Wednesday. The company has a market capitalization of $737.93 million, a price-to-earnings ratio of -16.73 and a beta of 0.69. Anavex Life Sciences has a 12-month low of $3.25 and a 12-month high of $14.44. The business has a 50-day moving average price of $9.92 and a 200 day moving average price of $7.70.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. As a group, equities research analysts predict that Anavex Life Sciences will post -0.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anavex Life Sciences

Several institutional investors have recently bought and sold shares of AVXL. Berkshire Money Management Inc. acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth about $107,000. Prudential Financial Inc. acquired a new stake in Anavex Life Sciences during the 4th quarter worth approximately $109,000. Fiduciary Alliance LLC purchased a new position in Anavex Life Sciences in the 4th quarter valued at approximately $119,000. D.A. Davidson & CO. acquired a new position in shares of Anavex Life Sciences in the fourth quarter worth $122,000. Finally, Orion Capital Management LLC increased its position in shares of Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 10,000 shares during the period. 31.55% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.